MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
JE · Effective Aug 8, 2022
15 active Medicare policies list D02.20, and 6 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J9 · Effective Oct 1, 2015
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
6 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of D02.20 |
|---|---|---|
| Brachytherapy | Jun 6, 2023 | Covered |
| Electrical Stimulation for Nausea, Vomiting, Motion Sickness and Other Selected Indications | Jan 5, 2024 | Covered |
| Lung Imaging: Selected Techniques | Nov 10, 2023 | Covered |
| Radiofrequency Tumor Ablation | Oct 6, 2023 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
National · Effective Aug 6, 2026
National · Effective Aug 13, 2026
J5 · Effective Aug 6, 2026
National · Effective Oct 30, 2025
National · Effective Jul 1, 2026
National · Effective Oct 1, 2026
| Policy | Effective | Status of D02.20 |
|---|
| Pulmonary Function Testing | Not recorded | Covered |
|---|